SCHEMBL30584888

SCHEMBL30584888

O=C(NCCCN1CCC(Oc2ccccc2)CC1)N1CCN(c2nc(-c3ccc(OC(F)(F)F)cc3)no2)CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DRD2 P14416 1/20 0.51
▸ DRD3 P35462 1/20 0.51
▸ MEN1 O00255 1/20 0.48
▸ KMT2A Q03164 1/20 0.48
▸ CHRM4 P08173 2/20 0.48
▸ LMNA P02545 4/20 0.46
▸ HTT P42858 3/20 0.46
▸ TP53 P04637 3/20 0.46
▸ TSHR P16473 2/20 0.46
▸ SMN1; SMN2 Q16637 2/20 0.46
▸ ALDH1A1 P00352 1/20 0.46
▸ GAA P10253 1/20 0.44
▸ MAPT P10636 4/20 0.43
▸ THRB P10828 1/20 0.43
▸ KCNH2 Q12809 1/20 0.42
▸ MCHR1 Q99705 1/20 0.42
▸ EPHX2 P34913 2/20 0.42
▸ CYP2C9 P11712 1/20 0.42
▸ CYP2J2 P51589 1/20 0.42
▸ FAAH O00519 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Formic Acid SCHEMBL30584798 0.87 MEN1 (0.56) DRD2DRD3MEN1KMT2ALMNA
SCHEMBL31546427 0.85 TSHR (0.50) MEN1KMT2ACHRM4LMNAHTT
SCHEMBL30584805 0.85 LMNA (0.48) DRD2DRD3MEN1KMT2ACHRM4
SCHEMBL30584818 0.81 MEN1 (0.60) MEN1KMT2ALMNAHTTTP53
SCHEMBL31667518 0.80 MAPT (0.45) MEN1KMT2ACHRM4LMNAHTT
SCHEMBL31546418 0.79 LMNA (0.72) MEN1KMT2ALMNAHTTTP53
SCHEMBL30584804 0.78 MEN1 (0.60) MEN1KMT2ALMNAHTTTP53
Formic Acid SCHEMBL30584790 0.77 MEN1 (0.56) MEN1KMT2ACHRM4LMNAHTT
Formic Acid SCHEMBL30584933 0.76 TSHR (0.65) MEN1KMT2ALMNAHTTTP53
SCHEMBL25434754 0.75 MEN1 (0.56) MEN1KMT2ACHRM4LMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4463452-B1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER ANIMA BIOTECH INC (US) 2025-07-30 — — EP disclosed
US-12344600-B2 c-Myc mRNA translation modulators and uses thereof in the treatment of cancer ANIMA BIOTECH INC. (US) 2025-07-01 — — US disclosed
US-20250109128-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER ANIMA BIOTECH INC. (US) 2025-04-03 — — US disclosed
EP-4463452-A2 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER Anima Biotech Inc. (US) 2024-11-20 — — EP disclosed
WO-2023177700-A2 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER ANIMA BIOTECH INC. (US) 2023-09-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12344600-B2 c-Myc mRNA translation modulators and uses thereof in the treatment of cancer MYC, MYCBP, MYCBP2 DRD2 4480/4885DRD3 4152/4885MEN1 1569/4885
US-20250109128-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER MYC, MYCBP, MYCBP2 DRD2 4480/4885DRD3 4152/4885MEN1 1569/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback